Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

References

Page 1

	Year	Citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, The Lancet Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicine	2021	1.5K
Teclistamab in Relapsed or Refractory Multiple Myeloma Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, New England Journal of Medicine	2022	990
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor–modified T cells Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger, Science Translational Medicine ImmunologyPathologyCd4 T Cell ResponsesT CellsImmunotherapy	2016	989
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells J. Joseph Melenhorst, Gregory M. Chen, Meng Wang, Nature Hematological MalignancyDecade-long Leukaemia RemissionsMalignant Blood DisorderT-regulatory CellImmunology	2022	851
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons, Nature Cd19-targeted T CellsCancer ImmunosurveillanceImmunologyTherapeutic EfficacyRegulatory T Cells	2018	829
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, New England Journal of Medicine	2019	655
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Shaji Kumar, Joseph Mıkhael, Francis K. Buadi, Mayo Clinic Proceedings Hematological MalignancyOncologyClinical EpidemiologyHematologyUpdated Mayo Stratification	2009	622
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Jesús F. San Miguel, Binod Dhakal, Kwee Yong, New England Journal of Medicine	2023	615
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Journal of Clinical Oncology	2022	580
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma Wanhong Zhao, Jie Liu, Baiyan Wang, Journal of Hematology & Oncology ImmunologyImmunodominanceImmunotherapeuticsPhase 1Immunotherapy	2018	526

Page 1